120 related articles for article (PubMed ID: 20646792)
1. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
Eur J Med Chem; 2010 Sep; 45(9):4035-42. PubMed ID: 20646792
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
[TBL] [Abstract][Full Text] [Related]
3. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
4. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
5. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
Boulamery A; Simon N; Vidal J; Bruguerolle B
Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.
Giorgioni G; Claudi F; Ruggieri S; Ricciutelli M; Palmieri GF; Di Stefano A; Sozio P; Cerasa LS; Chiavaroli A; Ferrante C; Orlando G; Glennon RA
Bioorg Med Chem; 2010 Mar; 18(5):1834-43. PubMed ID: 20153654
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents.
Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
Bioorg Med Chem Lett; 2013 Oct; 23(19):5279-82. PubMed ID: 23973169
[TBL] [Abstract][Full Text] [Related]
8. Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Kääriäinen TM; Käenmäki M; Forsberg MM; Oinas N; Tammimäki A; Männistö PT
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):162-70. PubMed ID: 21848668
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
10. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
11. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
12. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.
Bartus RT; Emerich D; Snodgrass-Belt P; Fu K; Salzberg-Brenhouse H; Lafreniere D; Novak L; Lo ES; Cooper T; Basile AS
J Pharmacol Exp Ther; 2004 Aug; 310(2):828-35. PubMed ID: 15039453
[TBL] [Abstract][Full Text] [Related]
13. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
14. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
16. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
17. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
18. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
